← Leaderboards
Robert House
Nanotherapeutics, Inc.
$3,149,878
Attributed
$3,149,878
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2M · FY2016–19$2.5M$1.9M$1.3M$625K$0
'16
'17
'18
'19
Funding mix
By agency
NIH$3,149,878 · 2
By mechanism
N01$3,149,878 · 2
Top collaborators
No co-investigators on record.
Most similar at Nanotherapeutics, Inc.
Same institution · by research overlap
- Milan Tomic$15,158,708
- Isabel Scholz$799,780
- James David Talton$15,179,333
- James Talton$155,864
- Joann Brown$14,084
Others in their field
Top investigators on “Botulism”
- Milan Tomic · Xoma Corporation$64,944,259
- James D. Marks · University Of California San Francisco$17,246,048
- Milan Tomic · Nanotherapeutics, Inc.$13,935,526
- Konstantin Ichtchenko · New York University School Of Medicine$12,971,230
- Joseph T. Barbieri · University Of Wisconsin-Madison$11,233,478
- Kim D Janda · Scripps Research Institute$10,059,209
Research focus
BotulismBaseBiodefenseBontoxilysinContractsMonoclonal AntibodiesMonoclonal Antibody ProductionPre-ClinicalProduct DevelopmentResearch And DevelopmentStability TestingSupport ContractsTherapeutic EvaluationAdvanced DevelopmentTherapeutic DevelopmentTherapeutic Candidate
Grant awards (4)
TASK B1: STABILITY TESTING OF THERAPEUTICS FOR BOTULISM$250,929
N01 · FY2019 · AI · contact PI
TASK B1: STABILITY TESTING OF THERAPEUTICS FOR BOTULISM$565,110
N01 · FY2017 · AI · contact PI
Production of monoclonal antibody-based therapeutics for botulism$283,967
N01 · FY2017 · AI · contact PI
Production of monoclonal antibody-based therapeutics for botulism$2,049,872
N01 · FY2016 · AI · contact PI